Diana Boraschi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4288557/publications.pdf

Version: 2024-02-01

138 papers	7,686 citations	57758 44 h-index	54911 84 g-index
146 all docs	146 docs citations	146 times ranked	12280 citing authors

#	Article	IF	Citations
1	Recombinant BCG Expressing the Subunit 1 of Pertussis Toxin Induces Innate Immune Memory and Confers Protection against Non-Related Pathogens. Vaccines, 2022, 10, 234.	4.4	5
2	Methodological Approaches To Assess Innate Immunity and Innate Memory in Marine Invertebrates and Humans. Frontiers in Toxicology, 2022, 4, 842469.	3.1	4
3	Helicobacter pylori Infection of Primary Human Monocytes Boosts Subsequent Immune Responses to LPS. Frontiers in Immunology, 2022, 13, 847958.	4.8	10
4	An Evolutionary and Environmental Perspective of the Interaction of Nanomaterials with the Immune System. Nanomaterials, 2022, 12, 957.	4.1	0
5	What Is IL-1 for? The Functions of Interleukin-1 Across Evolution. Frontiers in Immunology, 2022, 13, 872155.	4.8	20
6	Microplastics interact with SARS-CoV-2 and facilitate host cell infection. Environmental Science: Nano, 2022, 9, 2653-2664.	4.3	9
7	Towards bio-compatible magnetic nanoparticles: Immune-related effects, in-vitro internalization, and in-vivo bio-distribution of zwitterionic ferrite nanoparticles with unexpected renal clearance. Journal of Colloid and Interface Science, 2021, 582, 678-700.	9.4	27
8	A Step-by-Step Approach to Improve Clinical Translation of Liposome-Based Nanomaterials, a Focus on Innate Immune and Inflammatory Responses. International Journal of Molecular Sciences, 2021, 22, 820.	4.1	12
9	Interaction between Macrophages and Nanoparticles: In Vitro 3D Cultures for the Realistic Assessment of Inflammatory Activation and Modulation of Innate Memory. Nanomaterials, 2021, 11, 207.	4.1	15
10	Interaction of nanoparticles with endotoxin Importance in nanosafety testing and exploitation for endotoxin binding. Nanotoxicology, 2021, 15, 558-576.	3.0	16
11	Direct LC-MS/MS Analysis of Extra- and Intracellular Glycerophosphoinositol in Model Cancer Cell Lines. Frontiers in Immunology, 2021, 12, 646681.	4.8	4
12	Primary and Memory Response of Human Monocytes to Vaccines: Role of Nanoparticulate Antigens in Inducing Innate Memory. Nanomaterials, 2021, 11, 931.	4.1	5
13	SERS-based nanotoxicology assessment of gold nanoparticles. , 2021, , .		0
14	Personalised Profiling of Innate Immune Memory Induced by Nano-Imaging Particles in Human Monocytes. Frontiers in Immunology, 2021, 12, 692165.	4.8	10
15	Robust Immune Response Induced by Schistosoma mansoni TSP-2 Antigen Coupled to Bacterial Outer Membrane Vesicles. International Journal of Nanomedicine, 2021, Volume 16, 7153-7168.	6.7	4
16	SERS Sensing of Bacterial Endotoxin on Gold Nanoparticles. Frontiers in Immunology, 2021, 12, 758410.	4.8	14
17	Innate Memory Reprogramming by Gold Nanoparticles Depends on the Microbial Agents That Induce Memory. Frontiers in Immunology, 2021, 12, 751683.	4.8	3
18	The Interactions between Nanoparticles and the Innate Immune System from a Nanotechnologist Perspective. Nanomaterials, 2021, 11, 2991.	4.1	30

#	Article	IF	Citations
19	In Vitro and In Vivo Models to Assess the Immune-Related Effects of Nanomaterials. International Journal of Environmental Research and Public Health, 2021, 18, 11769.	2.6	11
20	Probing the immune responses to nanoparticles across environmental species. A perspective of the EU Horizon 2020 project PANDORA. Environmental Science: Nano, 2020, 7, 3216-3232.	4.3	17
21	The IL-1 family cytokines and receptors in autoimmune diseases. Autoimmunity Reviews, 2020, 19, 102617.	5.8	87
22	Profiling the Course of Resolving vs. Persistent Inflammation in Human Monocytes: The Role of IL-1 Family Molecules. Frontiers in Immunology, 2020, 11, 1426.	4.8	18
23	Induction of Innate Immune Memory by Engineered Nanoparticles in Monocytes/Macrophages: From Hypothesis to Reality. Frontiers in Immunology, 2020, 11, 566309.	4.8	18
24	The Impact of Nanoparticles on Innate Immune Activation by Live Bacteria. International Journal of Molecular Sciences, 2020, 21, 9695.	4.1	19
25	Addressing Nanomaterial Immunosafety by Evaluating Innate Immunity across Living Species. Small, 2020, 16, e2000598.	10.0	35
26	Gold Nanoparticles Modulate BCG-Induced Innate Immune Memory in Human Monocytes by Shifting the Memory Response towards Tolerance. Cells, 2020, 9, 284.	4.1	25
27	Inhibiting Monocyte Recruitment to Prevent the Pro-Tumoral Activity of Tumor-Associated Macrophages in Chondrosarcoma. Cells, 2020, 9, 1062.	4.1	11
28	One hits (almost) all. Nature Immunology, 2019, 20, 1095-1097.	14.5	2
29	In vitro Evidence of Human Immune Responsiveness Shows the Improved Potential of a Recombinant BCG Strain for Bladder Cancer Treatment. Frontiers in Immunology, 2019, 10, 1460.	4.8	21
30	Bovine colon organoids: From 3D bioprinting to cryopreserved multi-well screening platforms. Toxicology in Vitro, 2019, 61, 104606.	2.4	44
31	Surface Exposure of PEG and Amines on Biodegradable Nanoparticles as a Strategy to Tune Their Interaction with Protein-Rich Biological Media. Nanomaterials, 2019, 9, 1354.	4.1	14
32	Assessing Immunological Memory in the Solitary Ascidian Ciona robusta. Frontiers in Immunology, 2019, 10, 1977.	4.8	6
33	Cytokines and soluble receptors of the interleukin-1 family in Schnitzler syndrome. Scandinavian Journal of Rheumatology, 2019, 48, 235-238.	1.1	8
34	Interaction of engineered nanomaterials with the immune system: Health-related safety and possible benefits. Current Opinion in Toxicology, 2018, 10, 74-83.	5.0	8
35	The family of the interleukinâ€1 receptors. Immunological Reviews, 2018, 281, 197-232.	6.0	252
36	IL-1 family cytokines and soluble receptors in systemic lupus erythematosus. Arthritis Research and Therapy, 2018, 20, 27.	3.5	44

#	Article	IF	Citations
37	Personalized risk prediction of postoperative cognitive impairment â€“ rationale for the EU-funded BioCog project. European Psychiatry, 2018, 50, 34-39.	0.2	51
38	Oxidative Stress and Inflammation Induced by Environmental and Psychological Stressors: A Biomarker Perspective. Antioxidants and Redox Signaling, 2018, 28, 852-872.	5.4	62
39	IL-1 family cytokines and receptors in IgG4-related disease. Cytokine, 2018, 102, 145-148.	3.2	17
40	Circulating levels of IL-1 family cytokines and receptors in Alzheimerâ€™s disease: new markers of disease progression?. Journal of Neuroinflammation, 2018, 15, 342.	7.2	91
41	Innate Immune Memory: Time for Adopting a Correct Terminology. Frontiers in Immunology, 2018, 9, 799.	4.8	77
42	Innate Immune Memory in Invertebrate Metazoans: A Critical Appraisal. Frontiers in Immunology, 2018, 9, 1915.	4.8	121
43	IL-1 Family. , 2018, , 2530-2538.		0
44	IL-1 Receptor Family. , 2018, , 2539-2548.		0
45	Immune System. , 2017, , 313-337.		4
46	Development and Functional Differentiation of Tissue-Resident Versus Monocyte-Derived Macrophages in Inflammatory Reactions. Results and Problems in Cell Differentiation, 2017, 62, 23-43.	0.7	32
47	Nanoparticles and innate immunity: new perspectives on host defence. Seminars in Immunology, 2017, 34, 33-51.	5.6	244
48	Bacterial endotoxin (lipopolysaccharide) binds to the surface of gold nanoparticles, interferes with biocorona formation and induces human monocyte inflammatory activation. Nanotoxicology, 2017, 11, 1157-1175.	3.0	80
49	Different Regulation of Interleukin-1 Production and Activity in Monocytes and Macrophages: Innate Memory as an Endogenous Mechanism of IL-1 Inhibition. Frontiers in Pharmacology, 2017, 8, 335.	3.5	50
50	Endotoxin Contamination in Nanomaterials Leads to the Misinterpretation of Immunosafety Results. Frontiers in Immunology, 2017, 8, 472.	4.8	72
51	Induction of Innate Immune Memory by Engineered Nanoparticles: A Hypothesis That May Become True. Frontiers in Immunology, 2017, 8, 734.	4.8	29
52	Editorial: Interaction of Nanomaterials with the Immune System: Role in Nanosafety and Nanomedicine. Frontiers in Immunology, 2017, 8, 1688.	4.8	9
53	Editorial (Thematic Issue : Exploiting Knowledge on Nano-Immune Interactions: The Present and the) Tj ETQq1 1 0.784314 rgBT /Over	0.6	0
54	IL-1 Receptor Family. , 2017, , 1-10.		0

#	Article	IF	Citations
55	IL-1 Family. , 2017, , 1-9.		0
56	Editorial: Interaction Between the Immune System and Nanomaterials: Safety and Medical Exploitation. Current Bionanotechnology, 2016, 2, 3-5.	0.6	5
57	Assessing the Immunosafety of Engineered Nanoparticles with a Novel in Vitro Model Based on Human Primary Monocytes. ACS Applied Materials & Interfaces, 2016, 8, 28437-28447.	8.0	39
58	Modulation of Macrophage Activation. , 2016, , 123-149.		1
59	Poverty-Related Diseases College: a virtual African-European network to build research capacity. BMJ Global Health, 2016, 1, e000032.	4.7	3
60	Endotoxin contamination: a key element in the interpretation of nanosafety studies. Nanomedicine, 2016, 11, 269-287.	3.3	156
61	Engineered Nanoparticles and the Immune System: Interaction and Consequences. , 2016, , 205-226.		2
62	Pharmacological Strategies Using Biologics as Immunomodulatory Agents. , 2016, , 1-11.		0
63	From Antigen Delivery System to Adjuvanticy: The Board Application of Nanoparticles in Vaccinology. Vaccines, 2015, 3, 930-939.	4.4	52
64	New Insights Into Tissue Macrophages: From Their Origin to the Development of Memory. Immune Network, 2015, 15, 167.	3.6	53
65	Innate Immune Memory: The Latest Frontier of Adjuvanticity. Journal of Immunology Research, 2015, 2015, 1-7.	2.2	44
66	Vaccines of the Future: The Role of Inflammation and Adjuvanticity. Journal of Immunology Research, 2015, 2015, 1-2.	2.2	1
67	Optimising the use of commercial LAL assays for the analysis of endotoxin contamination in metal colloids and metal oxide nanoparticles. Nanotoxicology, 2015, 9, 462-473.	3.0	52
68	Transcriptomic Profiling of the Development of the Inflammatory Response in Human Monocytes In Vitro. PLoS ONE, 2014, 9, e87680.	2.5	81
69	From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation. Frontiers in Immunology, 2014, 5, 514.	4.8	1,499
70	Immunosenescence and vaccine failure in the elderly: Strategies for improving response. Immunology Letters, 2014, 162, 346-353.	2.5	78
71	Perspectives in immunopharmacology: The future of immunosuppression. Immunology Letters, 2014, 161, 211-215.	2.5	5
72	MafB is a downstream target of the IL-10/STAT3 signaling pathway, involved in the regulation of macrophage de-activation. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 955-964.	4.1	27

#	Article	IF	Citations
73	Induction of long-term immunity against respiratory syncytial virus glycoprotein by an osmotic polymeric nanocarrier. Acta Biomaterialia, 2014, 10, 4606-4617.	8.3	17
74	Nanoparticles and Immunological Frailty. , 2014, , 69-75.		2
75	Nanoparticles and Innate Immunity. , 2014, , 9-31.		0
76	Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis. Journal of Neuroinflammation, 2014, 11, 94.	7.2	74
77	Engineered nanoparticles. How brain friendly is this new guest?. Progress in Neurobiology, 2014, 119-120, 20-38.	5.7	111
78	Concern-driven integrated approaches to nanomaterial testing and assessment â€“ report of the NanoSafety Cluster Working Group 10. Nanotoxicology, 2014, 8, 334-348.	3.0	118
79	Challenges in the Design of Clinically Useful Brain-targeted Drug Nanocarriers. Current Medicinal Chemistry, 2014, 21, 4227-4246.	2.4	8
80	The interleukin-1 receptor family. Seminars in Immunology, 2013, 25, 394-407.	5.6	208
81	Free IL-18 and IL-33 cytokines in chronic spontaneous urticaria. Cytokine, 2013, 61, 741-743.	3.2	44
82	The Gracefully Aging Immune System. Science Translational Medicine, 2013, 5, 185ps8.	12.4	124
83	The bio-nano-interface in predicting nanoparticle fate and behaviour in living organisms: towards grouping and categorising nanomaterials and ensuring nanosafety by design. BioNanoMaterials, 2013, 14, .	1.4	27
84	Immunomodulatory Activity of a Novel, Synthetic Beta-glucan (Î²-glu6) in Murine Macrophages and Human Peripheral Blood Mononuclear Cells. PLoS ONE, 2013, 8, e80399.	2.5	13
85	Immune System. , 2012, , 169-184.		3
86	Interaction of nanoparticles with immunocompetent cells: nanosafety considerations. Nanomedicine, 2012, 7, 121-131.	3.3	100
87	Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents?. Drug Discovery Today, 2012, 17, 367-378.	6.4	87
88	Nano-immunosafety: issues in assay validation. Journal of Physics: Conference Series, 2011, 304, 012077.	0.4	5
89	IL-37: a new anti-inflammatory cytokine of the IL-1 family. European Cytokine Network, 2011, 22, 127-147.	2.0	302
90	Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects. Particle and Fibre Toxicology, 2011, 8, 8.	6.2	170

#	Article	IF	Citations
91	Towards nanotechnology regulation â€“ Publish the unpublishable. Nano Today, 2011, 6, 228-231.	11.9	16
92	PLGA nanoparticles surface decorated with the sialic acid, N-acetylneuraminic acid. Biomaterials, 2010, 31, 3395-3403.	11.4	64
93	IL-1 family nomenclature. Nature Immunology, 2010, 11, 973-973.	14.5	294
94	Immunomodulatory activity of andrographolide on macrophage activation and specific antibody response. Acta Pharmacologica Sinica, 2010, 31, 191-201.	6.1	100
95	Î²-Glucan Oligosaccharide EnhancesCD8+T Cells Immune Response Induced by a DNA Vaccine Encoding Hepatitis B Virus Core Antigen. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-10.	3.0	23
96	The suitability of different cellularin vitroimmunotoxicity and genotoxicity methods for the analysis of nanoparticle-induced events. Nanotoxicology, 2010, 4, 52-72.	3.0	94
97	Ageing and immunity. Vaccine, 2010, 28, 3627-3631.	3.8	53
98	Serum and urinary levels of IL-18 and its inhibitor IL-18BP in systemic lupus erythematosus. European Cytokine Network, 2010, 21, 264-71.	2.0	60
99	ILâ€18 Activity in Systemic Lupus Erythematosus. Annals of the New York Academy of Sciences, 2009, 1173, 301-309.	3.8	60
100	The immunostimulatory effect of ILâ€1Î² in vivo is blocked by antisense peptides complementary to the loop sequence 163â€“171. FEBS Letters, 2009, 583, 792-796.	2.8	9
101	Free circulating interleukin-18 is increased inÂSchnitzler syndrome: aÂnew autoinflammatory disease?. European Cytokine Network, 2009, 20, 108-111.	2.0	40
102	Immunity against HIV/AIDS, Malaria, and Tuberculosis during Co-Infections with Neglected Infectious Diseases: Recommendations for the European Union Research Priorities. PLoS Neglected Tropical Diseases, 2008, 2, e255.	3.0	34
103	Specific immune response to HBsAg is enhanced by Î²-glucan oligosaccharide containing an Î±-(1â†’3)-linked bond and biased towards M2/Th2. International Immunopharmacology, 2007, 7, 725-733.	3.8	37
104	Development of biologicals for the therapy of lupus erythematosus. Expert Review of Vaccines, 2007, 6, 1001-1011.	4.4	1
105	IL-18 in autoimmunity: review. European Cytokine Network, 2006, 17, 224-52.	2.0	172
106	Innate defence functions of macrophages can be biased by nano-sized ceramic and metallic particles. European Cytokine Network, 2004, 15, 339-46.	2.0	113
107	IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 14181-14186.	7.1	118
108	Glycosylation enhances functional stability of the chemotactic cytokine CCL2. European Cytokine Network, 2003, 14, 91-6.	2.0	26

#	Article	IF	Citations
109	Model of interaction of the IL-1 receptor accessory protein IL-1RAcP with the IL-1Î²/IL-1RIcomplex. FEBS Letters, 2001, 499, 65-68.	2.8	64
110	Lymphocytes from Autoimmune MRLlpr/lprMice Are Hyperresponsive to IL-18 and Overexpress the IL-18 Receptor Accessory Chain. Journal of Immunology, 2001, 166, 3757-3762.	0.8	36
111	The Membrane Form of the Type II IL-1 Receptor Accounts for Inhibitory Function. Journal of Immunology, 2000, 165, 3350-3357.	0.8	64
112	Role of Metalloproteases in the Release of the IL-1 type II Decoy Receptor. Journal of Biological Chemistry, 1997, 272, 31764-31769.	3.4	108
113	Purification of Human Recombinant Interleukin 1 Receptor Antagonist Proteins uponBacillus subtilisSporulation. Protein Expression and Purification, 1997, 9, 219-227.	1.3	9
114	Sporulation: An alternative way to recover recombinant proteins fromBacillus subtilis. Biotechnology and Bioengineering, 1995, 48, 197-200.	3.3	2
115	Identification of MIP-1Î±/LD78 as a Monocyte Chemoattractant Released by the HTLV-I-Transformed Cell Line MT4. AIDS Research and Human Retroviruses, 1995, 11, 155-160.	1.1	26
116	The Interleukin-1 System: Physiopathology and New Insights for its Therapeutical Potential. International Journal of Immunopathology and Pharmacology, 1992, 5, 115-122.	2.1	1
117	Binding and internalization of the 163â€“171 fragment of human IL-1Î². Cytokine, 1992, 4, 201-204.	3.2	18
118	Comparison of human interleukin-1Î² and its 163â€“171 peptide in bone resorption and the immune response. Cytokine, 1991, 3, 141-148.	3.2	32
119	Murine interferon-Î³/interleukin-1 fusion proteins used as antigens for the generation of hybridomas producing monoclonal anti-interleukin-1 antibodies. Cytokine, 1991, 3, 134-140.	3.2	12
120	Quantitation of biologically active IL-1 by a sensitive assay based on immobilized human IL-1 receptor type II (IL-1RII). Journal of Immunological Methods, 1991, 138, 31-38.	1.4	4
121	Antibacterial resistance induced by recombinant interleukin 1 in myelosuppressed mice: Effect of treatment schedule and correlation with colony-stimulating activity in the bloodstream. Cellular Immunology, 1990, 128, 250-260.	3.0	18
122	Differential activity of interleukin 1Î± and interleukin 1Î² in the stimulation of the immune responsein vivo. European Journal of Immunology, 1990, 20, 317-321.	2.9	57
123	Structure-function relationship of interleukin-1 giving new insights for its therapeutic potential. Biotherapy (Dordrecht, Netherlands), 1989, 1, 377-389.	0.7	20
124	One-step immunoaffinity purification of bioactive human recombinant IL-1Î² with a monoclonal antibody directed to a well-exposed domain of the protein. Journal of Immunological Methods, 1989, 123, 1-8.	1.4	12
125	Arachidonic acid metabolism in macrophages: Regulation by interferons and interleukin 1. International Journal of Immunopharmacology, 1985, 7, 359.	1.1	1
126	Natural antiviral activity of mouse macrophages against encephalomyocarditis virus. Antiviral Research, 1985, 5, 217-227.	4.1	3

#	Article	IF	Citations
127	Macrophage antitumor activity: impaired responsiveness to interferon-Î³ of macrophages from genetically defective mice. European Journal of Immunology, 1984, 14, 1061-1063.	2.9	7
128	Macrophage Antitumor Activity in vitro. Comparative Analysis of Cytolytic, Cytostatic, and Cytotoxic Activities of Mouse Macrophages and Human Monocytes. Immunobiology, 1984, 166, 251-262.	1.9	13
129	Chemotactic activity for mononuclear phagocytes of culture supernatants from murine and human tumor cells: Evidence for a role in the regulation of the macrophage content of neoplastic tissues. International Journal of Cancer, 1983, 31, 55-63.	5.1	55
130	Macrophage activation by interferon: dissociation between tumoricidal capacity and suppressive activity. European Journal of Immunology, 1982, 12, 320-326.	2.9	42
131	Interferon-induced enhancement of macrophage-mediated tumor cytolysis and its difference from activation by lymphokines. European Journal of Immunology, 1981, 11, 110-114.	2.9	42
132	Natural killer activity of gut mucosal lymphoid cells in mice. European Journal of Immunology, 1981, 11, 919-922.	2.9	82
133	Effects of in vivo treatments with cyclosporin-A on mouse cell-mediated immune responses. International Journal of Immunopharmacology, 1981, 3, 357-364.	1.1	36
134	Species-restricted effects of human and mouse lymphokines on macrophages. European Journal of Immunology, 1980, 10, 542-546.	2.9	13
135	Macrophage activation for tumor cytotoxicity: Genetic variation in macrophage tumoricidal capacity among mouse strains. Cellular Immunology, 1979, 45, 188-194.	3.0	59
136	Oxidative Stress and Inflammation Induced by Environmental and Psychological Stressors: A Biomarker Perspective. SSRN Electronic Journal, 0, , .	0.4	0
137	Gold Nanoparticles contaminated by Bacterial Endotoxin: biophysical characterization, imaging and nanotoxicology. , 0, , .		0
138	The SARS-CoV-2 Nucleoprotein Induces Innate Memory in Human Monocytes. Frontiers in Immunology, 0, 13, .	4.8	3